Skip to main content

Table 1 Demographic and baseline characteristics (safety analysis set)

From: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

 

Treatment A

Treatment B

 
 

PP 150 mg eq.

PP 50-150 mg eq.

Total

 

(N = 186)

(N = 26)

(N = 212)

Age (years)

Mean (SD)

41.4 (10.24)

35.7 (8.17)

40.7 (10.17)

Sex, n (%)

   

Men

138 (74)

16 (62)

154 (73)

Women

48 (26)

10 (38)

58 (27)

Race, n (%)

White

88 (47)

8 (31)

96 (45)

Black

36 (19)

6 (23)

42 (20)

Asian

60 (32)

12 (46)

72 (34)

Othera

2 (1)

0

2 (< 1)

Ethnicity, n (%)

Not Hispanic or Latino

184 (99)

24 (92)

208 (98)

Hispanic or Latino

2 (1)

2 (8)

4 (2)

Weight (kg)

   

Mean (SD)

78.1 (18.55)

73.5 (16.45)

77.5 (18.33)

Height (cm)

   

Mean (SD)

170.6 (10.24)

171.0 (9.97)

170.6 (10.18)

Baseline body mass index (kg/m 2)

Category, n (%)

   

Normal < 25

70 (38)

14 (54)

84 (40)

Overweight 25- < 30

66 (35)

7 (27)

73 (34)

Obese ≥ 30

50 (27)

5 (19)

55 (26)

Mean (SD)

26.71 (5.55)

24.91 (4.16)

26.49 (5.42)

Psychiatric Evaluations b

   

PANSS total scores, Mean (SD)

55.5 (8.87)

51.5 (9.86)

55.0 (9.08)

PSP, Mean (SD)

67.3 (10.41)

68.0 (10.01)

67.4 (10.33)

CGI-S, Median (Range)

3.0 (2;6)

3.0 (2;5)

3.0 (2;6)

  1. a includes native Hawaiian or other Pacific islander; b For PANSS and PSP: n = 178 (Treatment A), n = 26 (Treatment B), and n = 204 (Total); For CGI-S: n = 182 (Treatment A), n = 26 (Treatment B), and n = 208 (Total); PANSS- Positive and Negative Syndrome scale; PSP- Personal and Social Performance Scale; CGI-S- Clinical Global Impression Severity Score; PP- Paliperidone palmitate, BMI- Body Mass Index